Comparing the current results to its competitors, Novocure Limited reported Revenue increase in the 2 quarter 2026 by 15.6 % year on year. The revenue growth was below Novocure Limited's competitors' average revenue growth of 16.28 %, achieved in the same quarter.
Novocure Limited's Comment on Competition and Industry Peers
The market for cancer treatments is highly competitive and rapidly evolving, driven by new product introductions and activities of industry participants. Competition factors include treatment effectiveness, side effects, cost, reimbursement availability, and market acceptance. The company holds an expanding intellectual property portfolio related to TTFields therapy, which may limit competitors from introducing advanced TTFields devices. However, competitors may offer less sophisticated devices using expired patents or operate in regions with limited intellectual property enforcement. Some third parties in the United States and China are developing devices and seeking intellectual property protection related to TTFields therapy. Although early patents began expiring in 2021, new entrants must conduct clinical studies and regulatory submissions to obtain approval while avoiding infringement. The company competes with others commercializing or investigating anti-cancer therapies for glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC), pancreatic cancer, malignant pleural mesothelioma (MPM), and other indications, some of which exclude patients treated with the company's products. The introduction of competing therapies could materially affect the company's business and financial results. The company and its products are subject to extensive regulation by the U.S. Food and Drug Administration (FDA) and other regulatory authorities worldwide.
June 2, 2025
As the fight against pancreatic cancer continues, Novocure Limited (NASDAQ: NVCR) has made significant strides in its development of Tumor Treating Fields (TTFields) therapy. The company announced that results from the Phase 3 PANOVA-3 trial of TTFields for pancreatic cancer will be unveiled at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, with additional publication in the Journal of Clinical Oncology. The results promise a clinically meaningful and statistically significant improvement in treatment outcomes, potentially changing the landscape for this difficult-to-treat cancer.In the PANOVA-3 trial, Novocure’s TTFields technology, which utilizes low-intensity, ...
April 23, 2025
In recent years, the landscape of oncology has seen remarkable advances, particularly in innovative therapeutic approaches aimed at treating challenging cancer types. Novocure, a pioneering company in the development of Tumor Treating Fields (TTFields) therapy, has emerged as a leader in this domain, presenting promising results through an array of clinical trials. Notably, the company is poised to make a significant impact with its upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, set to take place in Chicago from May 30 to June 3.One of the cornerstones of Novocure’s clinical research is the Phase 3 PANOVA-3 trial, which evaluates the use of TTFields in conju...
October 15, 2024
In a significant advance in cancer therapeutics, Novocure (NASDAQ: NVCR), a pioneering company in cancer treatment technologies, has received the green light from the U.S. Food and Drug Administration (FDA) for its innovative product, Optune Lua. This groundbreaking approval allows Optune Lua to be used concurrently with PD-1 and PD-L1 inhibitors, or docetaxel, to treat adult patients suffering from metastatic non-small cell lung cancer (mNSCLC) who have seen disease progression post a platinum-based regimen. Understanding the Treatment Landscape Metastatic non-small cell lung cancer is one of the most challenging oncological adversaries, notorious for its aggressiveness and high mortality rates. Treatment ...
June 3, 2024
Metis Phase 3 Clinical Trial Demonstrates Significant Progress in Delaying Brain Metastasis with Improved Quality of Life, as Novocure Releases Promising Data at ASCO 2024ROOT, Switzerland - Novocure (NASDAQ: NVCR) has made a groundbreaking announcement during the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The company revealed the results of its phase 3 METIS clinical trial, which focused on the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These results have showcased significant improvements in delaying time to intracranial progression, along with enhanced quality of life deterioration-...
March 28, 2024
Novocure s METIS Phase-3 Clinical Trial for Non-Small-Cell Lung Cancer (NSCLC) has achieved its primary endpoint, signifying a statistical improvement in the time until intracranial progression in adult patients with 1-10 brain metastases from NSCLC, the company announced today. The patients in the study received Tumor Treating Fields (TTFields) and supportive care, compared to those who received supportive care alone.TTFields technology, developed by the global healthcare company Novocure, uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancerous cells to die. Novocure is headquartered in Root, Switzerland, and is listed on the NAS...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization.
Northwest Biotherapeutics Inc's business model focuses on the development and commercialization of personalized immunotherapy products for the treatment of cancer.
Sources:
Novocure Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Novocure Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
